hero image

Biogen Announces Webcast of Annual Meeting of Stockholders

June 5, 2019 News Release

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2019 Annual Meeting of Stockholders will be held on Wednesday, June 19, 2019 at 9:00 a.m. Eastern Daylight Time.  A live audio webcast of the meeting will be available on the Investor Relations section of the Company's corporate website at www.biogen.com/investors or directly via www.virtualshareholdermeeting.com/BIIB2019. An archive of the webcast will be available for replay following the meeting.  Please allow at least 10 minutes prior to the event to visit the site and download the necessary software to listen to the webcast.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
  
Contact:
Karen Jewell
Investor Relations
Biogen
781-464-2442

thumb
January 26, 2023
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines

thumb
January 18, 2023
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS FEBRUARY 15, 2023

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2022 financial results Wednesday, February 15, 2023, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at